Expression of Her-2 in gastric cancer and targeted therapy
10.3969/j.issn.1002-3070.2014.02.018
- VernacularTitle:胃癌Her-2的表达与靶向治疗
- Author:
Xi ZHANG
;
Yingwei XUE
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
Her-2;
Targeted therapy
- From:
Practical Oncology Journal
2014;(2):177-181
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of gastric cancer is in the fourth place of all cancers in worldwide ,and the fatal-ity rate is in the second place .Standard chemotherapy regimens play an important role in prolonging gastric cancer survival rate.However,most of gastric cancers are in advanced stage when diagnose is finally made .The current medical practice can only meet the limited treatment options .In the last several decades ,study of the molecular mechanisms of gastric cancer gets constant new progress .By inhibiting the human epidermal growth factor receptor 2(Her-2)for advanced gastric cancer,it provides a new treatment for patients.Trastuzumab is a kind of Her -2 monoclonal antibody .It is the first kind of targeted therapy drug for the treatment of metastatic gastric cancer .A combination of trastuzumab with cisplatin and 5-fluorouracil based chemotherapy benefits gastric cancer overall survival.Overexpression of Her -2 provides evidence for the targeted therapy .So we reviewed Her -2 excessive expression of gastric carcinoma in recent years and represented by bead sheet resistance to targeted therapy .In this paper ,research of overpression of Her -2 and targeted threrapy in gastric cancer are summarized .
